Boehringer-Ingelheim

An extended labeling claim has added detection of three additional EGFR mutations to help ID NSCLC patients for whom Boehringer Ingelheim's Gilotrif is indicated.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.  

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

Poor patient health, tumor histology, insufficient tissue samples, and long turnaround times are some reasons doctors gave for not using EGFR status to determine care.

New survival data suggest that patients with del19 mutations should receive Gilotrif as their top option and that researchers should no longer clump different EGFR-mutated subpopulations together in research, lead study investigator Lecia Sequist said.

NEW YORK (GenomeWeb) – IDBS said this week the Boehringer Ingelheim is using IDBS' E-WorkBook Suite to help streamline and improve its research and development efforts.

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network's Oncology Research Program has awarded grants to four researchers who will investigate the efficacy of the drug nintedanib in non-small cell lung, colorectal, and gastrointestinal cancers.

Pages

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.